Select therapeutic use:
Indications for ELLA:
Prevention of pregnancy following unprotected intercourse or known or suspected contraceptive failure. Not for use as regular contraceptive.
Take 1 tab as soon as possible within 120hrs (5 days) after unprotected intercourse or contraceptive failure. May repeat dose if vomiting occurs within 3hrs.
Premenarchal: not applicable.
Known/suspected pregnancy (Cat.X).
Not for termination of an existing pregnancy. Exclude pregnancy before prescribing. Rule out ectopic pregnancy if lower abdominal pain occurs. Rule out pregnancy if subsequent menses delayed by >1 week. Does not protect against STDs/HIV (AIDS). Repeat use within same menstrual cycle: not recommended. Postmenopausal women, nursing mothers: not recommended.
Drugs (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, topiramate) or herbals (eg, St. John's wort) that induce certain enzymes (eg, CYP3A4) may decrease effectiveness. May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole). May antagonize regular hormonal contraceptives; use barrier contraception for remainder of menstrual cycle. May potentiate P-gp substrates (eg, dabigatran etexilate, digoxin).
Headache, abdominal pain, nausea, dysmenorrhea, fatigue, dizziness; menstrual cycle changes.